Endpoints News 生物医药· Maggie Fick·· 6 天前AI 评分35
Argenx 花费数十亿美元推进Vyvgart
Argenx is spending billions to push beyond Vyvgart
AI 导读
Argenx 公司新任 CEO Karen Massey 在任六个月期间,已监督完成了两项合计价值约 34 亿美元的收购,旨在推动Vyvgart的发展。
正文
Six months into her term as CEO of rare disease drugmaker argenx, Karen Massey has overseen two acquisitions worth a combined potential of about $3.4 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news